US 2026/0308162 A1 · PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

OwnerAyman Allian, Jayanthy Jayanth +17inventors

InventorsAyman Allian, Jayanthy Jayanth, Mohamed-Eslam F. Mohamed, Mathew M. Mulhern, Fredrik Lars Nordstrom, Ahmed A. Othman, Michael J. Rozema, Lakshmi Bhagavatula, Patrick J. Marroum, Peter T. Mayer, Ahmad Y. Sheikh, Thomas B. Borchardt, Ben Klünder, Heidi S. Camp, Robert J. Padley, Jeffrey W. Voss, Andrea Chiricozzi, Andreas Lazar, Henrique D. Teixeira

Life of this patent

Estimating the term…

Abstract

The present disclosure is directed to methods for treating alopecia areata (AA) using the selective JAK1 inhibitor upadacitinib.

Claims20

Dependent claims

A method of treating a human patient having alopecia areata, the method comprising orally administering once daily to the patient 15 mg of upadacitinib.

Dependencies are inferred from the claim text.

Facts

Application

19/566,828Filed 13 Mar 2026

Priority

16 Oct 2015

Published

8 Oct 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification22 codes

C07D 487/14
In which the condensed system contains three hetero rings: ortho-condensed systems
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 31/4985
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: pyrazines or piperazines…
A61K 47/02
Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents…:…

Family

Application62/242,797Us provisional application · filed 16 Oct 2015

Application62/267,672Us provisional application · filed 15 Dec 2015

Application62/301,537Us provisional application · filed 29 Feb 2016

Application62/352,380Us provisional application · filed 20 Jun 2016

Application15/295,561Continuation · filed 17 Oct 2016

Application15/891,012Continuation · filed 7 Feb 2018

Application16/656,237Continuation · filed 17 Oct 2019

Application17/184,194Continuation · filed 24 Feb 2021

Application17/902,690Continuation · filed 2 Sep 2022

Application18/137,804Continuation · filed 21 Apr 2023

Application63/531,443Us provisional application · filed 8 Aug 2023

Application18/533,564Continuation · filed 8 Dec 2023

Application18/797,097Continuation · filed 7 Aug 2024

Application18/812,217Continuation · filed 22 Aug 2024

Application19/086,824Continuation in part · filed 21 Mar 2025

Application19/174,569Continuation in part · filed 9 Apr 2025

Application19/284,585Continuation · filed 29 Jul 2025

Application19/566,828Continuation

Application19/284,585Continuation in part

Application19/174,569Continuation

Application19/086,824Continuation

US 2017/0129902 A1Published application

US 2019/0023714 A1Published application

US 2020/0291040 A1Published application

US 2021/0363149 A1Published application

US 2025/0049789 A1Published application

US 2026/0308162 A1This patent

From the US filing history. Foreign family members aren’t listed.